Last year GSK made a strategic move to focus solely on biopharma, and it is already realizing the benefits of a more targeted business.
Tag Archive for: Xevudy
GSK beat third-quarter earnings forecasts on Wednesday and raised its 2022 estimate for the second time in four months, continuing its strong start as a standalone prescription medicine business since spinning off its consumer health unit.